Skip to main content
. Author manuscript; available in PMC: 2018 Aug 1.
Published in final edited form as: Breast. 2017 Jul 4;34(Suppl 1):S19–S26. doi: 10.1016/j.breast.2017.06.022

Figure 2. Rates of pathological complete response (pCR) by hormone receptor status of the primary tumor in published neoadjuvant trials of single or dual anti-HER2 therapy.

Figure 2

Abbreviations: pCR, pathological complete response; L, lapatinib; P, pertuzumab; T, trastuzumab. *, treatment arms without chemotherapy; a,b, treatment arms included 5-fluorouracil, epirubicin, cyclophosphamide, and docetaxel with different schedules; c, treatment arm included docetaxel and carboplatin. Numbers on top of the bars indicate pCR rate (%).